ATE492543T1 - 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidi - 2-one als cb1-rezeptor-modulatoren - Google Patents

1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidi - 2-one als cb1-rezeptor-modulatoren

Info

Publication number
ATE492543T1
ATE492543T1 AT07871197T AT07871197T ATE492543T1 AT E492543 T1 ATE492543 T1 AT E492543T1 AT 07871197 T AT07871197 T AT 07871197T AT 07871197 T AT07871197 T AT 07871197T AT E492543 T1 ATE492543 T1 AT E492543T1
Authority
AT
Austria
Prior art keywords
dihydropyrrolidi
benzylamino
diphenyl
receptor modulators
modulators
Prior art date
Application number
AT07871197T
Other languages
English (en)
Inventor
David Scott Coffey
Jingdan Hu
Stacy Jo Keding
Joseph Herman Junior Krushinski
John Mehnert Schaus
David Edward Tupper
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE492543T1 publication Critical patent/ATE492543T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07871197T 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidi - 2-one als cb1-rezeptor-modulatoren ATE492543T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
PCT/US2007/082042 WO2008070306A2 (en) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamin0-1,5-dihydr0pyrr0lidin-2-0ne as cb1 receptor modulators

Publications (1)

Publication Number Publication Date
ATE492543T1 true ATE492543T1 (de) 2011-01-15

Family

ID=39386481

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07871197T ATE492543T1 (de) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidi - 2-one als cb1-rezeptor-modulatoren

Country Status (23)

Country Link
US (2) US7998985B2 (de)
EP (2) EP2094684B1 (de)
JP (2) JP5331001B2 (de)
KR (2) KR101088236B1 (de)
CN (2) CN101528733B (de)
AR (1) AR063497A1 (de)
AT (1) ATE492543T1 (de)
AU (1) AU2007329808B2 (de)
BR (1) BRPI0717347A2 (de)
CA (2) CA2667210C (de)
CL (1) CL2007003002A1 (de)
CY (1) CY1111140T1 (de)
DE (1) DE602007011495D1 (de)
DK (2) DK2099784T3 (de)
EA (2) EA015745B1 (de)
ES (2) ES2398388T3 (de)
MX (2) MX2009004054A (de)
PE (1) PE20080926A1 (de)
PL (2) PL2094684T3 (de)
PT (2) PT2099784E (de)
SI (2) SI2094684T1 (de)
TW (1) TW200825067A (de)
WO (2) WO2008070305A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
AU2009238444B2 (en) * 2008-04-22 2013-08-29 Eli Lilly And Company 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
WO2009131815A1 (en) 2008-04-22 2009-10-29 Eli Lilly And Company 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
US20110280813A1 (en) * 2008-11-13 2011-11-17 Alice Prince Neuraminidase inhibitors and uses thereof
ITTO20110641A1 (it) * 2010-07-15 2012-01-16 Oleg Iliich Epshtein Composizioni farmaceutiche e metodi di trattamento
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US20240158384A1 (en) * 2020-12-14 2024-05-16 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
JP2007523128A (ja) 2004-02-19 2007-08-16 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Ｃｂ１−アンタゴニスト活性を有するイミダゾリン誘導体
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds

Also Published As

Publication number Publication date
WO2008070306A3 (en) 2008-07-31
AR063497A1 (es) 2009-01-28
TW200825067A (en) 2008-06-16
AU2007329807A1 (en) 2008-06-12
WO2008070305A2 (en) 2008-06-12
PL2099784T3 (pl) 2013-05-31
PT2099784E (pt) 2013-01-04
MX2009004054A (es) 2009-04-27
US8168659B2 (en) 2012-05-01
WO2008070306A2 (en) 2008-06-12
CN101528732B (zh) 2013-04-03
PE20080926A1 (es) 2008-07-19
EA015175B1 (ru) 2011-06-30
KR101088229B1 (ko) 2011-11-30
US20090275618A1 (en) 2009-11-05
DK2094684T3 (da) 2011-03-14
BRPI0717347A2 (pt) 2014-01-14
CN101528733A (zh) 2009-09-09
JP2010507590A (ja) 2010-03-11
JP5331001B2 (ja) 2013-10-30
JP5331002B2 (ja) 2013-10-30
ES2356025T3 (es) 2011-04-04
CL2007003002A1 (es) 2008-06-06
EP2094684B1 (de) 2010-12-22
DK2099784T3 (da) 2013-01-14
US20100016375A1 (en) 2010-01-21
EA200970405A1 (ru) 2009-12-30
AU2007329808B2 (en) 2013-11-07
CN101528732A (zh) 2009-09-09
MX2009004053A (es) 2009-04-27
KR20090071613A (ko) 2009-07-01
ES2398388T3 (es) 2013-03-15
EP2099784A2 (de) 2009-09-16
WO2008070305A3 (en) 2008-08-28
CY1111140T1 (el) 2015-06-11
CA2667210A1 (en) 2008-06-12
CA2667372C (en) 2013-09-03
CA2667372A1 (en) 2008-06-12
KR101088236B1 (ko) 2011-11-30
SI2094684T1 (sl) 2011-04-29
SI2099784T1 (sl) 2013-02-28
JP2010507589A (ja) 2010-03-11
EP2099784B1 (de) 2012-12-12
DE602007011495D1 (de) 2011-02-03
EA015745B1 (ru) 2011-10-31
US7998985B2 (en) 2011-08-16
CA2667210C (en) 2013-09-24
KR20090069316A (ko) 2009-06-30
CN101528733B (zh) 2013-10-16
PT2094684E (pt) 2011-01-28
EA200970404A1 (ru) 2009-10-30
EP2094684A2 (de) 2009-09-02
AU2007329808A1 (en) 2008-06-12
PL2094684T3 (pl) 2011-05-31

Similar Documents

Publication Publication Date Title
DE602007006531D1 (de) Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
FR2897076B1 (fr) Cable composite elastique pour pneumatique.
BRPI0922911A2 (pt) "unidade de cilindro de gás".
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
IL198990A0 (en) Cb1 receptor modulators
ATE513831T1 (de) Pyridinä3,4-büpyrazinone
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
ATE492543T1 (de) 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidi - 2-one als cb1-rezeptor-modulatoren
ATE538091T1 (de) Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
IL191767A0 (en) Imidazoles as gaba-b receptor modulators
BRPI0923048A2 (pt) "composto de aminopirazol".
BRPI0813230A2 (pt) Moduladores de calicreína 7
DK2000920T3 (da) Netværkssystem
BRPI0822061A2 (pt) Moduladores do receptor canabinoide
DE602007005775D1 (en) 6-phenyl-1h-imidazoä4, 5-cüpyridin-4-carbonitril-derivate als cathepsin-k- und -s-hemmer
BRPI0816154A2 (pt) Moduladores canabinóides de 5-vinilfenil-1-fenil-pirazol substituídos
ITBO20060029U1 (it) Attacco per cerniera.
GB0622569D0 (en) Cannabinoid receptor modulators
ATE537166T1 (de) Piperidylpropanthiole als ccr3-modulatoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2094684

Country of ref document: EP